Kyntra Bio
KYNB
144 hedge funds and large institutions have $767M invested in Kyntra Bio in 2017 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 51 increasing their positions, 43 reducing their positions, and 11 closing their positions.
91% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 11
19% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 43
16% more capital invested
Capital invested by funds: $661M → $767M (+$106M)
3% more funds holding
Funds holding: 140 → 144 (+4)
0.01% less ownership
Funds ownership: 1.95% → 1.95% (-0.01%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
52% less call options, than puts
Call options by funds: $4.08M | Put options by funds: $8.42M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$108M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.57M |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$5.48M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.24M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$4.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
PointState Capital
New York
|
-$17.7M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$15.7M |
| 3 |
Millennium Management
New York
|
-$7.09M |
| 4 |
Morgan Stanley
New York
|
-$3.24M |
| 5 |
NC
Nexthera Capital
New York
|
-$2.48M |
KYNB Hedge Fund Activity: Q1 2017 in Review
144 of the 4,033 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q1 2017, worth a combined $767M — up 16% from $661M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new KYNB positions and 11 closed out — a net gain of 10 holders — while 51 added to existing stakes and 43 trimmed.
The largest buyer was BlackRock, adding an estimated $108M. The largest seller was PointState Capital, exiting entirely with an estimated $17.7M sold.
- 144 institutional investors held Kyntra Bio (KYNB) as of Q1 2017, up from 140 in Q4 2016.
- Funds reported $767M of Kyntra Bio stock for Q1 2017, up 16% quarter-over-quarter.
- 21 funds opened new Kyntra Bio positions in Q1 2017 and 11 closed out, a net change of +10 holders.
- The largest Kyntra Bio buyer in Q1 2017 was BlackRock, an estimated $108M added.
- The largest Kyntra Bio seller in Q1 2017 was PointState Capital, an estimated $17.7M sold.
Based on aggregated 13F filings for Q1 2017.